--- title: CDMOs offering Sterile Fill-Finish & Aseptic Manufacturing with Gene Therapy path: /explore/sterile-fill-finish/gene-therapy companies_count: 22 --- # CDMOs offering Sterile Fill-Finish & Aseptic Manufacturing with Gene Therapy 22 published CDMOs match Sterile Fill-Finish & Aseptic Manufacturing and Gene Therapy. Locations in this set include United States, China, United Kingdom, Denmark, Japan, and France. Capabilities that show up most often in this set: CMC Analytical Development, Process Development, CMC Regulatory Submission Support, Viral Vector Manufacturing, and Quality Control Testing. ## Matching companies - [AGC Biologics](/companies/agcbio) - Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities. - [Aldevron](/companies/aldevron) - Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization. - [Argonaut Manufacturing Services](/companies/argonautms) - Argonaut is a sterile fill-finish CDMO specializing in isolator-based aseptic manufacturing for biologics, peptides, nucleic acids, lipid nanoparticles, gene therapies, and vaccines from preclinical through commercial scale, with FDA and Annex 1 compliance. - [Ascend](/companies/ascend-adv) - Ascend is a gene-to-GMP development partner specializing in advanced biologics and vaccines with 60+ years of custom biologics expertise and 20+ years of AAV development capability. The company offers onsite fill-finish capabilities across multiple US locations and combines next-generation technologies with deep regulatory acumen. - [Ascendia Pharmaceutical Solutions](/companies/ascendiacdmo) - Ascendia is a specialty CDMO providing formulation development, analytical services, and GMP manufacturing for small molecules and biologics from pre-formulation through commercialization, with proprietary nanotechnologies including LipidSol, EmulSol, AmorSol, and NanoSol. - [Biomay AG](/companies/biomay) - GMP CDMO specializing in plasmid DNA, mRNA, and recombinant protein manufacturing from gene construction to market supply, with in-house mRNA lipid-nanoparticle formulation and aseptic fill-finish capabilities. - [Boston Institute of Biotechnology, LLC](/companies/bostonbib) - Full-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L. - [CDMO Network](/companies/cdmonetwork) - CDMO Network is a biomanufacturing partner-routing platform that connects biotech sponsors with specialized CDMO partners across modalities, development stages, and geographies to reduce integration friction and accelerate program execution. - [Catalent](/companies/catalent) - Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply. - [Charles River Laboratories](/companies/criver) - Charles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years. - [FUJIFILM Biotechnologies](/companies/fujifilm-biotechnologies) - CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities. - [Forge Biologics](/companies/forgebiologics) - Dedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance. - [National Resilience](/companies/resilience) - End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities. - [Oxford Biomedica](/companies/oxb) - Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs. - [Patheon (Thermo Fisher Pharma Services)](/companies/patheon) - Patheon is a trusted global contract development and manufacturing organization (CDMO) partner owned by Thermo Fisher Scientific, offering 360° integrated solutions from early-stage R&D through clinical supply and commercial manufacturing. - [Pharmaron](/companies/pharmaron) - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK. - [Porton Advanced](/companies/porton-advanced) - End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe. - [Siegfried Holding](/companies/siegfried) - Global CDMO with 16 production sites across four continents, offering integrated development and manufacturing from early-phase to commercial scale for drug substance and drug product. - [Symbiosis Pharmaceutical Services](/companies/symbiosis-pharma) - UK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules. - [Syngene International](/companies/syngeneintl) - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.